About Careers MedBlog Contact us

Bioblast Pharma’s Experimental Muscle Wasting Drug Offers Hope

by Shirley Johanna on October 28, 2015 at 10:23 AM
Font : A-A+

Bioblast Pharma’s Experimental Muscle Wasting Drug Offers Hope

BioBlast Pharma announced promising results from a Phase 2 clinical study of its lead experimental drug to treat patients with rare muscle wasting disorder.

The company said its lead drug in development, Cabaletta, hit the main goal of proving to be safe and tolerable in the study on patient suffering from oculopharyngeal muscular dystrophy.


BioBlast said the drug improved patients' muscle function while also reducing difficulty in swallowing.

Oculopharyngeal muscular dystrophy is a rare disease where patients develop swallowing difficulties, which could lead to death in severe cases.

The company said it would discuss results from this study and a second mid-stage study with the U.S. Food and Drug Administration before it started a late-stage study.

Source: Medindia

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Bioblast Pharma’s Experimental Muscle Wasting Drug Offers Hope Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests